Evaluation of the diagnostic value of YiDiXie™-SS, YiDiXie™-HS and YiDiXie™-D in brain malignant tumors - Wu, Yutong; Sun, Chen; Ge, Zhenjian; Zhou, Huimei; Li, Xutai; Chen, Wenkang; Li, Yingqi; Lin, Shengjie; Zhang, Pengwu; Wang, Wuping; Chen, Siwei; Li, Wei; et al. (medRxiv, 2024)
Background Brain malignant tumors is a serious threat to human health and causes heavy economic burden. Enhanced MRI is widely used in the diagnosis of brain tumors. However, false-positive results of enhanced MRI will bring unnecessary mental pain, expensive examination costs, physical injuries, and other adverse consequences; while false-negative results of enhanced MRI bring delayed treatment, and patients will thus have to bear the adverse consequences of poor prognosis, high treatment costs, poor quality of life, and short survival period. There is an urgent need to find convenient, cost-effective and non-invasive diagnostic methods to reduce the false-negative and false-positive rates of brain-enhanced MRI. The aim of this study was to evaluate the diagnostic value of YiDiXie™-SS, YiDiXie™-HS and YiDiXie™-D in brain malignant tumors.Patients and methods 235 subjects (malignant group, n=75; benign group, n=160) were finally included in this study. Remaining serum samples from the subjects were collected and tested by applying the YiDiXie™ all-cancer detection kit to evaluate the sensitivity and specificity of YiDiXie™-SS, YiDiXie™-HS and YiDiXie™-D.Results The sensitivity of YiDiXie™-SS in enhanced MRI-positive patients was 98.4% (95% CI: 91.3% - 99.9%; 60/61) and its specificity was 62.5% (95% CI: 38.6% - 81.5%; 10/16). This means that the application of YiDiXie ™ -SS reduces the false-positive rate of brain enhanced MRI by 62.5% (95% CI: 38.6% - 81.5%; 10/16) with essentially no increase in malignancy leakage. The sensitivity of YiDiXie™-HS in enhanced MRI-negative patients was 85.7% (95% CI: 60.1% - 97.5%; 12/14) and its specificity was 84.7% (95% CI: 78.0% - 89.7%; 122/144). This means that the application of YiDiXie™-HS reduces the false-negative rate of brain-enhanced MRI by 85.7% (95% CI: 60.1% - 97.5%; 12/14). The sensitivity of YiDiXie™ -D in enhanced MRI-positive patients was 34.4% (95% CI: 23.7% - 47.0%; 21/61) and its specificity was 93.8% (95% CI: 71.7% - 99.7%; 15/16). This means that the application of YiDiXie™-HS reduces the false-positive rate of brain-enhanced MRI by 93.8% (95% CI: 71.7% - 99.7%; 15/16).Conclusion YiDiXie™-SS significantly reduces the false-positive rate of brain-enhanced MRI without increasing the delay in treatment of malignant tumors. YiDiXie™-HS dramatically reduces the false-negative rate of brain-enhanced MRI. YiDiXie ™ -D dramatically reduces the false-positive rate of brain-enhanced MRI. The YiDiXie ™ test has significant diagnostic value in brain tumors, and is expected to solve the problems of “high false-negative rate of enhanced MRI” and “high false-positive rate of enhanced MRI” in brain tumors.Clinical trial number ChiCTR2200066840.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialChiCTR2200066840Funding StatementThis work was supported by Shenzhen High-level Hospital Construction Fund, Clinical Research Project of Peking University Shenzhen Hospital (LCYJ2020002, LCYJ2020015, LCYJ2020020, LCYJ2017001).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of Peking University Shenzhen Hospital gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are contained in the manuscript.